The article presents the results of sociological assessment of commitment to treatment of repeatedly hospitalized patients in hospitals of the Irkutsk Oblast and the Republic of Buryatia, that permitted to study their medical and social characteristics, the level of awareness of their own health, their diseases and methods of their treatment are presented. Sampling was preceded by the selection of respondents with the support of experts that reduced the impact on the study results of various factors, along with commitment to treatment, which determines the effectiveness of the treatment process (effective treatment methods for the relevant nosology, quality of medical care, etc.). The reasons for re-hospitalization were studied. The factors resulting in incomplete implementation and rejection of medical recommendations, as well as factors contributing to increased commitment to treatment were analyzed. It was established that three out of four respondents are not committed to therapy, respondents were poorly informed about the normal and their own most important indices of their health. Only one out of five of respondents indicated that they comply with medical recommendations in fullness. The main reasons for commitment to treatment are the factors that are managed by the health care system: detailed information about the disease and prescribed treatment, attention given by the doctor to their patients in accordance with their needs.

Download full-text PDF

Source
http://dx.doi.org/10.32687/0869-866X-2019-27-6-1070-1074DOI Listing

Publication Analysis

Top Keywords

commitment treatment
20
treatment
9
medical recommendations
8
commitment
5
[the sociological
4
sociological evaluation
4
evaluation commitment
4
treatment re-hospitalized
4
re-hospitalized patients]
4
patients] article
4

Similar Publications

Trends in the epidemiology of intravascular device-associated bacteremia among French hematology patients: insights from the SPIADI prospective multicenter study, 2020-2024.

Ann Hematol

January 2025

Mission Nationale Surveillance et Prévention des Infections Associées aux Dispositifs Invasifs (SPIADI), Centre d'Appui pour la Prévention des Infections Associées aux Soins en région Centre val de Loire, Centre Hospitalier Régional Universitaire, Hôpital Bretonneau, Tours, France.

Hematology patients require central venous catheters for cancer treatment and nutrition, which increases their risk of intravascular device-associated bacteremia. In the absence of recent data, we investigated intravascular device-associated bacteremia in this specific context. A three-month surveillance was conducted annually in 27 hematology wards, using a protocol derived from the HAI-Net ICU ECDC protocol (2020-2024).

View Article and Find Full Text PDF

Background: The 2021 WHO report highlights the importance of global planning for dementia. Initiatives that unite and support young leaders and stakeholders from diverse backgrounds in dementia care & research are crucial. The G8 Summit on Dementia in 2013 led to the creation of the World Dementia Council and the World Young Leaders in Dementia (WYLD) network, which connects professionals to work together on finding solutions to dementia challenges.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

NA, Charlottesville, VA, USA.

Preclinical Alzheimer's prevention trials require a multi-year commitment from diverse, cognitively unimpaired individuals willing to receive biomarker results of confirmed Alzheimer's pathology and possible ApoE4 status. Participants learn new terms such as ARIA, edema and microhemorrhage and undergo numerous MRI scans for safety monitoring. They take quarterly composite Alzheimer's assessments that are anxiety-provoking and highlight weaknesses which may have been unrecognized in daily life.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

GloNeuro Academy, Noida, Uttar Pradesh, India.

Background: Alzheimer's disease (AD) remains a formidable neurodegenerative challenge, characterized by profound cognitive decline. Despite decades of research, effective disease-modifying therapies are elusive. Recent advances in molecular neuropharmacology have unveiled potential therapeutic targets for AD, offering renewed hope.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!